FB418

N/A

Report date: 2023/11/01 20:08:59
NME

Base Information

Drug NameFB418
Drug Alias NameFB418
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionABL proto-oncogene 1 inhibitorsLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsABL proto-oncogene 1Leucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsAmyotrophic Lateral SclerosisParkinson DiseaseParkinsonian Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator Companies1st Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active Companies1st Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisParkinson DiseaseParkinsonian Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A